Expert Interview
Digging into the Phase 1 data for REGN's LAG3 + Libtayo combination in frontline Melanoma
Ticker(s): REGN, BMYInstitution: Center for Cancer Immune Therapy, Herlev Hospital
- Associate Professor in Clinical Oncology & Junior Research Group Leader (TIL group) at Herlev Hospital, University of Copenhagen.
- Key interest in cancer immunotherapy and treatment of metastatic melanoma with reaerch focused on novel immune resistance and extensive clinical and translational research in TIL treatment
- Clinician-scientist with 50% time dedicated to clinical duties; works in an experimental cancer treatment unit and treats around 60 patients/month with cancer immunotherapy – the vast majority with melanoma.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
